Clonal hematopoiesis in sickle cell disease

BACKGROUND: Curative gene therapies for sickle cell disease (SCD) are currently undergoing clinical evaluation. The occurrence of myeloid malignancies in these trials has prompted safety concerns. Individuals with SCD are predisposed to myeloid malignancies, but the underlying causes remain undefine...

Descripción completa

Detalles Bibliográficos
Autores principales: Liggett, L. Alexander, Cato, Liam D., Weinstock, Joshua S., Zhang, Yingze, Nouraie, S. Mehdi, Gladwin, Mark T., Garrett, Melanie E., Ashley-Koch, Allison, Telen, Marilyn J., Custer, Brian, Kelly, Shannon, Dinardo, Carla L., Sabino, Ester C., Loureiro, Paula, Carneiro-Proietti, Anna B., Maximo, Cláudia, Reiner, Alexander P., Abecasis, Gonçalo R., Williams, David A., Natarajan, Pradeep, Bick, Alexander G., Sankaran, Vijay G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843701/
https://www.ncbi.nlm.nih.gov/pubmed/34990411
http://dx.doi.org/10.1172/JCI156060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843701/
https://www.ncbi.nlm.nih.gov/pubmed/34990411
http://dx.doi.org/10.1172/JCI156060

Ejemplares similares